Inside the secondary analysis, the significantly less conservative but clinically meaningful criterion of secure response (defined as a 50% or more reduction in MADRS from baseline for 2 weeks) was used. Of the patients who achieved steady reaction, 25.8% during the esketamine group and 57.six% inside the placebo group relapsed, https://emersonq900qgu8.blog-eye.com/profile